(12) United States Patent (10) Patent No.: US 8.236,308 B2 Kischel Et Al
USOO82363.08B2 (12) United States Patent (10) Patent No.: US 8.236,308 B2 Kischel et al. (45) Date of Patent: Aug. 7, 2012 (54) COMPOSITION COMPRISING McLaughlin et al., Cancer Immunol. Immunother, 1999.48, 303 CROSS-SPECIES-SPECIFIC ANTIBODES 3.11. AND USES THEREOF The U.S. Department of Health and Human Services Food and Drug Administration, Center for Biologics Evaluation and Research, “Points to Consider in the Manufacture and Testing of Monoclonal (75) Inventors: Roman Kischel, Karlsfeld (DE); Tobias Antibody Products for Human Use.” pp. 1-50 Feb. 28, 1997.* Raum, München (DE); Bernd Hexham et al., Molecular Immunology 38 (2001) 397-408.* Schlereth, Germering (DE); Doris Rau, Gallart et al., Blood, vol.90, No. 4 Aug. 15, 1997: pp. 1576-1587.* Unterhaching (DE); Ronny Cierpka, Vajdos et al., J Mol Biol. Jul. 5, 2002:320(2):415-28.* München (DE); Peter Kufer, Moosburg Rudikoff et al., Proc. Natl. Acad. Sci. USA, 79: 1979-1983, Mar. (DE) 1982.* Colman P. M., Research in Immunology, 145:33-36, 1994.* (73) Assignee: Micromet AG, Munich (DE) International Search Report for PCT International Application No. PCT/EP2006/009782, mailed Nov. 7, 2007 (6 pgs.). *) Notice: Subject to anyy disclaimer, the term of this Bortoletto Nicola et al., “Optimizing Anti-CD3Affinity for Effective patent is extended or adjusted under 35 T Cell Targeting Against Tumor Cells'. European Journal of Immu U.S.C. 154(b) by 491 days. nology, Nov. 2002, vol. 32 (11), pp. 3102-3107. (XPO02436763). Fleiger, D. et al., “A Bispecific Single-Chain Antibody Directed Against EpCAM/CD3 in Combination with the Cytokines Interferon (21) Appl.
[Show full text]